Condition
Newly Diagnosed Philadelphia Chromosome Negative
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Erwinia Chrysanthemi Asparaginase
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Withdrawn1
Clinical Trials (1)
Research Network
Common Treatments
- Erwinia Chrysanthemi Asparaginase1
Active Sponsors
- Jazz Pharmaceuticals1
- Memorial Sloan Kettering Cancer Center1
Top Investigators
Memorial Sloan Kettering Cancer Center
Related Conditions
- Acute Lymphoblastic Leukemia All1
- Aged 60 Years Or Older1